Compare Huntington Ingalls Industries Inc (HII) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Huntington Ingalls Industries Inc trades at $265.14 (market cap $10.16B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Huntington Ingalls Industries Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.14% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 30 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| HII | HNGE | |
|---|---|---|
Market Cap | $10.16B | $8.48B |
Volume | 503,029 | 879,799 |
Sector | Industrials | Health |
52-Week High | $453.73 | $105.14 |
52-Week Low | $257.05 | $31.17 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $13.08B | $8.10B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
